Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRXCUQ)

Drug Name
SPL-108 Drug Info
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [1]
Ovarian epithelial cancer 2C73 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DMRXCUQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Extracellular matrix receptor III (CD44)
Drug Name Drug ID Indication ICD 11 Highest Status REF
A-6 DM6ZIES Macular degeneration 9B78.3 Phase 2 [3]
BIWA 4 DM61JH5 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Bivatuzumab mertansine DM0DO4S Solid tumour/cancer 2A00-2F9Z Terminated [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Extracellular matrix receptor III (CD44) TTWFBT7 CD44_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of Splash Pharmaceuticals.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Modulation of CD44 Activity by A6-Peptide.Front Immunol.2015 Mar 30;6:135.
4 A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72.